Sudo Biosciences announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital, Monograph Capital, and Eventide Asset Management as well as existing investors Frazier Life Sciences and Velosity Capital.
December 20, 2023
· 4 min read